These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 30873381)

  • 41. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of H3K27M mutation in cases of brain stem subependymoma.
    Yao K; Duan Z; Wang Y; Zhang M; Fan T; Wu B; Qi X
    Hum Pathol; 2019 Feb; 84():262-269. PubMed ID: 30389438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
    Vitanza NA; Monje M
    Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S
    Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.
    Xu C; Liu X; Geng Y; Bai Q; Pan C; Sun Y; Chen X; Yu H; Wu Y; Zhang P; Wu W; Wang Y; Wu Z; Zhang J; Wang Z; Yang R; Lewis J; Bigner D; Zhao F; He Y; Yan H; Shen Q; Zhang L
    Oncotarget; 2017 Sep; 8(44):76644-76655. PubMed ID: 29100338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
    Lobon-Iglesias MJ; Giraud G; Castel D; Philippe C; Debily MA; Briandet C; Fouyssac F; de Carli E; Dufour C; Valteau-Couanet D; Sainte-Rose C; Blauwblomme T; Beccaria K; Zerah M; Puget S; Calmon R; Boddaert N; Bolle S; Varlet P; Grill J
    J Neurooncol; 2018 Mar; 137(1):111-118. PubMed ID: 29198053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials.
    Damodharan S; Lara-Velazquez M; Williamsen BC; Helgager J; Dey M
    J Pers Med; 2022 May; 12(5):. PubMed ID: 35629262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The H3K36me2 writer-reader dependency in H3K27M-DIPG.
    Yu JR; LeRoy G; Bready D; Frenster JD; Saldaña-Meyer R; Jin Y; Descostes N; Stafford JM; Placantonakis DG; Reinberg D
    Sci Adv; 2021 Jul; 7(29):. PubMed ID: 34261657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC).
    Fonseca A; Afzal S; Bowes L; Crooks B; Larouche V; Jabado N; Perreault S; Johnston DL; Zelcer S; Fleming A; Scheinemann K; Silva M; Vanan MI; Mpofu C; Wilson B; Eisenstat DD; Lafay-Cousin L; Hukin J; Hawkins C; Bartels U; Bouffet E
    J Neurooncol; 2020 Aug; 149(1):45-54. PubMed ID: 32632896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liquid biopsy for diffuse intrinsic pontine glioma: an update.
    Lu VM; Power EA; Zhang L; Daniels DJ
    J Neurosurg Pediatr; 2019 Nov; 24(5):593-600. PubMed ID: 31491754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
    Gwak HS; Park HJ
    Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case Report: Low-grade glioma with
    Bernstock JD; Karandikar PV; Chen JA; Seidlitz J; Friedman GK; Meredith DM; Liu KX; Haas-Kogan D; Reardon DA; Peruzzi PP
    Front Surg; 2024; 11():1356660. PubMed ID: 38840975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
    Majzner RG; Ramakrishna S; Yeom KW; Patel S; Chinnasamy H; Schultz LM; Richards RM; Jiang L; Barsan V; Mancusi R; Geraghty AC; Good Z; Mochizuki AY; Gillespie SM; Toland AMS; Mahdi J; Reschke A; Nie EH; Chau IJ; Rotiroti MC; Mount CW; Baggott C; Mavroukakis S; Egeler E; Moon J; Erickson C; Green S; Kunicki M; Fujimoto M; Ehlinger Z; Reynolds W; Kurra S; Warren KE; Prabhu S; Vogel H; Rasmussen L; Cornell TT; Partap S; Fisher PG; Campen CJ; Filbin MG; Grant G; Sahaf B; Davis KL; Feldman SA; Mackall CL; Monje M
    Nature; 2022 Mar; 603(7903):934-941. PubMed ID: 35130560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma.
    Zhang Q; Yang L; Liu YH; Wilkinson JE; Krainer AR
    Sci Transl Med; 2023 Apr; 15(691):eadd8280. PubMed ID: 37043556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
    Lu VM; Alvi MA; McDonald KL; Daniels DJ
    J Neurosurg Pediatr; 2019 Mar; 23(3):308-316. PubMed ID: 30544362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.
    Nonnenbroich LF; Bouchal SM; Millesi E; Rechberger JS; Khatua S; Daniels DJ
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
    Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
    Duchatel RJ; Mannan A; Woldu AS; Hawtrey T; Hindley PA; Douglas AM; Jackson ER; Findlay IJ; Germon ZP; Staudt D; Kearney PS; Smith ND; Hindley KE; Cain JE; André N; La Madrid AM; Nixon B; De Iuliis GN; Nazarian J; Irish K; Alvaro F; Eisenstat DD; Beck A; Vitanza NA; Mueller S; Morris JC; Dun MD
    Neurooncol Adv; 2021; 3(1):vdab169. PubMed ID: 34988452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine.
    Green AL; Flannery P; Hankinson TC; O'Neill B; Amani V; DeSisto J; Knox A; Chatwin H; Lemma R; Hoffman LM; Mulcahy Levy J; Raybin J; Hemenway M; Gilani A; Koschmann C; Dahl N; Handler M; Pierce A; Venkataraman S; Foreman N; Vibhakar R; Wempe MF; Dorris K
    Neurooncol Adv; 2020; 2(1):vdaa021. PubMed ID: 32642682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.